Basket cover image
15 handpicked stocks

The Post-Pandemic Pediatric Pivot

The FDA's potential withdrawal of Pfizer's COVID vaccine for young children is reshaping the pediatric pharmaceutical landscape. This regulatory shift could create a significant market opening for other drugmakers focused on pediatric vaccines and therapies.

stock
stock
stock
stock
stock
stock
stock
stock
stock
stock

+5

Author avatar

Han Tan | Market Analyst

Updated 1 day ago | Published at August 13

Top Picks from This Group

Here are a few of the assets in this group. Create an account to unlock the full list.

PCVX

Vaxcyte Inc

PCVX

Current price

$31.55

KIDS

ORTHOPEDIATRICS CORP

KIDS

Current price

$20.09

HLVX

HILLEVAX, INC.

HLVX

Current price

$2.13

About This Group of Stocks

1

Our Expert Thinking

The FDA's potential withdrawal of Pfizer's COVID vaccine for young children signals a major regulatory shift in pediatric healthcare. This creates a market opening for companies with established or developing pipelines in pediatric vaccines and infectious disease treatments, positioning them to capture emerging opportunities in this specialised healthcare segment.

2

What You Need to Know

This group focuses on pharmaceutical companies operating in the pediatric healthcare space, particularly those developing vaccines and therapies for children's infectious diseases. These firms conduct clinical trials and research to bring new treatments to market, representing a niche but critical segment of the healthcare industry with potential for increased investment focus.

3

Why These Stocks

These companies were handpicked by professional analysts based on their potential to benefit from regulatory changes in the pediatric pharmaceutical market. Each firm has established or developing capabilities in pediatric vaccines and therapies, positioning them to attract increased funding and capture market share as the competitive landscape evolves.

12 Month Growth Potential

Use the growth calculator to see how much investing in these assets could return over one year.

If you invested across these assets:

in 12 months it could be worth:

$1,000.00

+357.22%

Group Performance Snapshot

357.22%

Average 12 Month Profit

On average, analysts expect assets in this group to grow 357.22% over the next year.

11 of 13

Stocks Rated Buy by Analysts

11 of 13 assets in this group are rated Buy by professional analysts.

0.8%

Group Growth

This group averaged a 0.8% return last month.

Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.

Why You'll Want to Watch These Stocks

🔄

Regulatory Shift Creating Opportunities

The FDA's potential withdrawal of a major pediatric COVID vaccine is reshaping the market landscape. Companies positioned in pediatric healthcare could benefit from this significant regulatory change.

🎯

Niche Market with High Barriers

Pediatric pharmaceuticals represent a specialised segment with complex regulatory requirements. Firms with established expertise in this area have competitive advantages that are difficult to replicate.

💡

Expert-Identified Market Gap

Professional analysts have identified these companies as potentially well-positioned to capture emerging opportunities in the evolving pediatric vaccine and therapy market.

Why Invest with Nemo Money?

Nemo Logo Fade
🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

💰

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Discover More Opportunities

AI's App Store Showdown

AI's App Store Showdown

Elon Musk's threat of an antitrust lawsuit against Apple highlights the growing tension between AI developers and the powerful app store gatekeepers. This situation could create opportunities for other technology companies that offer alternative platforms or help developers navigate the competitive app landscape.

View stocks
Navigating The Fed's Inflation Dilemma

Navigating The Fed's Inflation Dilemma

A recent spike in inflation, driven by import tariffs, has put the Federal Reserve in a difficult position. This theme focuses on companies that could benefit from this economic tension, whether through competitive pricing or a potential interest rate cut.

View stocks
Grounded Giant: Rivals Poised To Gain From Air Canada Strike

Grounded Giant: Rivals Poised To Gain From Air Canada Strike

A potential strike at Air Canada threatens to ground the nation's largest airline, creating significant travel disruption. This presents a tactical opportunity for rival airlines to capture market share and benefit from the surge in demand from displaced travelers.

View stocks
View All Stock Groups

Frequently Asked Questions

Everything you need to know about the product and billing.